Evaluation of Long-Term Clinical Acceptability and Satisfaction With the IC-8 Intraocular Lens
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cataract
- Sponsor
- AcuFocus, Inc.
- Enrollment
- 64
- Locations
- 7
- Primary Endpoint
- TCNVA
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the long-term clinical acceptability and overall satisfaction with the IC-8 IOL at least 12 months post-IOL implantation.
Detailed Description
This will be a prospective, multi-center, non-interventional study in up to 80 patients previously implanted with an IC-8 IOL contralaterally or bilaterally under the protocol ACU-P14-029 at up to nine clinical sites within Europe. The purpose of this study is to demonstrate the long-term clinical acceptability and overall satisfaction in patients implanted with the IC-8 IOL. The primary study endpoint is binocular target-corrected near visual acuity (TCNVA) of 20/32 or better in 85% or more patients at least 12 months post-implantation. The secondary study endpoint is overall satisfaction with postoperative vision in 85% or more patients reporting either satisfied or very satisfied at least 12 months post-implantation.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients previously implanted contralaterally or bilaterally with the IC-8 IOL under the protocol ACU-P14-029 and have had the IOL implanted for a duration of at least 12 months and currently have the IC-8 IOL in the eye.
- •Availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures at the study visit.
- •Signed informed consent.
Exclusion Criteria
- •Patients who have developed systemic or ocular pathology, not related to the IOL that affected their best corrected distance visual acuity to be 0.8 decimal or worse as determined by diagnostic testing or investigator's medical judgment. -
Outcomes
Primary Outcomes
TCNVA
Time Frame: 12 months
Binocular target-corrected near visual acuity (TCNVA) of 20/32 or better in 85% or more patients.
Secondary Outcomes
- Overall Satisfaction(12 months)